IFX est-elle associée à un taux sérique d'IFX plus bas à J1 ou J2 ?, p.99 ,
104 VII. Discussion, p.105 ,
biologiques et endoscopiques (scores) ont été exprimées en médianes et valeurs extrêmes (minimum -maximum) ,
8) dans le groupe témoin. Nous n'avons pas mis en évidence d'association statistiquement significative entre la présence de SEG et le taux initial d'albumine : p = 0,07. IX. Bibliographie 1 Infliximab for induction and maintenance therapy for ulcerative colitis, N. Engl. J. Med, vol.2419353, pp.6-27, 2005. ,
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis, Gastroenterology, vol.146, issue.1, pp.85-95, 2014. ,
DOI : 10.1053/j.gastro.2013.05.048
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis, Gastroenterology, vol.142, issue.2, pp.257-265, 2012. ,
DOI : 10.1053/j.gastro.2011.10.032
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial, Gut, vol.60, issue.6, pp.780-787, 2011. ,
DOI : 10.1136/gut.2010.221127
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial, The Lancet, vol.380, issue.9857, pp.1909-1924, 2012. ,
DOI : 10.1016/S0140-6736(12)61084-8
URL : https://hal.archives-ouvertes.fr/hal-00742308
Review article: the practical management of acute severe ulcerative colitis, Alimentary Pharmacology & Therapeutics, vol.25, issue.6 Suppl. ,
DOI : 10.1111/apt.13491
Predictors of early response to infliximab in patients with ulcerative colitis, Inflammatory Bowel Diseases, vol.13, issue.2, pp.123-128, 2007. ,
DOI : 10.1002/ibd.20054
An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.13, issue.2, pp.330-335, 2015. ,
DOI : 10.1016/j.cgh.2014.07.041
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis, Gut, vol.59, issue.01, pp.49-54, 2010. ,
DOI : 10.1136/gut.2009.183095
Tu1278 Infliximab and Adalimumab Serum Levels Predict Probability of Mucosal Healing, Gastroenterology, vol.148, issue.4, p.846, 2015. ,
DOI : 10.1016/S0016-5085(15)32866-3
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis, Gastroenterology, vol.149, issue.2, pp.350-355, 2015. ,
DOI : 10.1053/j.gastro.2015.04.016
New trends in inflammatory bowel disease epidemiology and disease course in Eastern Europe, Digestive and Liver Disease, vol.45, issue.4, pp.269-276, 2013. ,
DOI : 10.1016/j.dld.2012.08.020
Epidemiology of inflammatory bowel diseases: New insights from a French population-based registry (EPIMAD), Digestive and Liver Disease, vol.45, issue.2, pp.89-94 ,
DOI : 10.1016/j.dld.2012.09.005
URL : https://hal.archives-ouvertes.fr/tel-00820631
Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease, The American Journal of Gastroenterology, vol.31, issue.11, pp.3236-3244, 1999. ,
DOI : 10.1111/j.1572-0241.1999.01526.x
Diagnosis and management of primary sclerosing cholangitis, Hepatology, vol.44, issue.Suppl. 2, p.660, 2010. ,
DOI : 10.1002/hep.23294
New genes in inflammatory bowel disease: lessons for complex diseases?, The Lancet, vol.367, issue.9518, pp.1271-84, 2006. ,
DOI : 10.1016/S0140-6736(06)68345-1
Genetics and pathogenesis of inflammatory bowel disease, Nature, vol.105, issue.7351, pp.307-324, 2011. ,
DOI : 10.1038/nature10209
Analysis of bacterial bowel communities of IBD patients: What has it revealed?, Inflammatory Bowel Diseases, vol.14, issue.6, pp.858-67, 2008. ,
DOI : 10.1002/ibd.20392
URL : https://hal.archives-ouvertes.fr/hal-00652970
The gut microbiota in IBD, Nature Reviews Gastroenterology & Hepatology, vol.252, issue.10, pp.599-608, 2012. ,
DOI : 10.1038/nrgastro.2012.152
species in ulcerative colitis, Colorectal Disease, vol.54, issue.5, pp.161-170, 2014. ,
DOI : 10.1111/codi.12503
A meta-analysis of the role of smoking in inflammatory bowel disease, Digestive Diseases and Sciences, vol.284, issue.12, pp.1841-54, 1989. ,
DOI : 10.1007/BF01536701
Smoking, Physical Activity, Nutrition and Lifestyle: Environmental Factors and Their Impact on IBD, Digestive Diseases, vol.28, issue.3, pp.411-418, 2010. ,
DOI : 10.1159/000320395
URL : https://hal.archives-ouvertes.fr/hal-00593814
Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies, The American Journal of Gastroenterology, vol.112, issue.1, pp.171-177, 2000. ,
DOI : 10.1016/S0002-9270(98)00576-0
Appendectomy and Protection against Ulcerative Colitis, New England Journal of Medicine, vol.344, issue.11, pp.808-822, 2001. ,
DOI : 10.1056/NEJM200103153441104
Dietary Intake and Risk of Developing Inflammatory Bowel Disease: A Systematic Review of the Literature, The American Journal of Gastroenterology, vol.19, issue.4, pp.563-73, 2011. ,
DOI : 10.1136/bmj.280.6210.293-a
The Risk of Oral Contraceptives in the Etiology of Inflammatory Bowel Disease: A Meta-Analysis, The American Journal of Gastroenterology, vol.316, issue.6 Suppl, pp.2394-400, 2008. ,
DOI : 10.1111/j.1572-0241.2008.02064.x
Evidence that Stress Contributes to Inflammatory Bowel Disease: Evaluation, Synthesis, and Future Directions, Inflammatory Bowel Diseases, vol.11, issue.6, pp.600-608, 2005. ,
DOI : 10.1097/01.MIB.0000161919.42878.a0
Stressful Life Events as a Risk Factor for Inflammatory Bowel Disease Onset: A Population-Based Case?Control Study, The American Journal of Gastroenterology, vol.136, issue.1, pp.122-153, 2007. ,
DOI : 10.1136/jech.55.10.716
The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion ,
ROR??-Expressing Th17 Cells Induce Murine Chronic Intestinal Inflammation via Redundant Effects of IL-17A and IL-17F, Gastroenterology, vol.136, issue.1, pp.257-67, 2009. ,
DOI : 10.1053/j.gastro.2008.10.018
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo, Nature Medicine, vol.16, issue.11, pp.583-591, 2000. ,
DOI : 10.1038/nm1110-1341
Colonoscopy of acute colitis, Digestive Diseases and Sciences, vol.21, issue.suppl, pp.1550-1557, 1994. ,
DOI : 10.1007/BF02088063
Prise en charge d???une colite aigu?? grave, Gastroent??rologie Clinique et Biologique, vol.32, issue.12, pp.1030-1037, 2008. ,
DOI : 10.1016/j.gcb.2008.10.005
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis, Journal of Crohn's and Colitis, vol.6, issue.10, pp.965-90, 2012. ,
DOI : 10.1016/j.crohns.2012.09.003
Course of ulcerative colitis: Analysis of changes in disease activity over years, Gastroenterology, vol.107, issue.1, pp.3-11, 1994. ,
DOI : 10.1016/0016-5085(94)90054-X
Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis, Clinical Gastroenterology and Hepatology, vol.14, issue.9, 2016. ,
DOI : 10.1016/j.cgh.2016.01.015
General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence study, Gut, vol.42, issue.2, pp.175-184, 1998. ,
DOI : 10.1136/gut.42.2.175
A reproducible grading scale for histological assessment of inflammation in ulcerative colitis, Gut, vol.47, issue.3, pp.404-409, 2000. ,
DOI : 10.1136/gut.47.3.404
The pattern and outcome of acute severe colitis, Journal of Crohn's and Colitis, vol.4, issue.4, pp.431-438, 2010. ,
DOI : 10.1016/j.crohns.2010.02.001
Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies, BMJ, vol.335, issue.7628, p.1033, 2007. ,
DOI : 10.1136/bmj.39345.714039.55
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis, Gastroenterology, vol.132, pp.763-786, 2007. ,
The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. ECCO guidelines, Journal of Crohn's and Colitis, pp.239-254, 2016. ,
European evidence based consensus for endoscopy in inflammatory bowel disease, Journal of Crohn's and Colitis, vol.7, issue.12, pp.982-1018, 2013. ,
DOI : 10.1016/j.crohns.2013.09.016
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS), Gut, vol.61, issue.4, pp.535-542, 2012. ,
DOI : 10.1136/gutjnl-2011-300486
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management, Journal of Crohn's and Colitis, vol.6, issue.10, pp.991-1030, 2012. ,
DOI : 10.1016/j.crohns.2012.09.002
Mesalamine Protects Against Colorectal Cancer in Inflammatory Bowel Disease, Digestive Diseases and Sciences, vol.23, issue.11 Pt1, pp.1696-703, 2010. ,
DOI : 10.1007/s10620-009-0942-x
5-Aminosalicylic Acid Is Not Protective Against Colorectal Cancer in Inflammatory Bowel Disease: A Meta-Analysis of Non-Referral Populations, The American Journal of Gastroenterology, vol.107, issue.9, pp.1298-130, 2012. ,
DOI : 10.1053/j.gastro.2010.02.007
Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.11, p.4118, 2012. ,
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis ,
DOI : 10.1002/14651858.CD000543.pub3
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis ,
DOI : 10.1002/14651858.CD000544.pub3
Long-Term Mesalamine Maintenance in Ulcerative Colitis, Inflammatory Bowel Diseases, vol.19, issue.6, pp.1123-1132, 2013. ,
DOI : 10.1097/MIB.0b013e318280b1b8
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis, Gut, vol.55, issue.1, pp.47-53, 2006. ,
DOI : 10.1136/gut.2005.068809
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.9, p.478, 2012. ,
Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial, J Crohns Colitis, vol.5, p.13, 2011. ,
Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine, Gut, vol.56, issue.10, pp.1404-1413, 2007. ,
DOI : 10.1136/gut.2006.114363
URL : https://hal.archives-ouvertes.fr/hal-00815835
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, Journal of Crohn's and Colitis, vol.3, issue.2, pp.47-91, 2009. ,
DOI : 10.1016/j.crohns.2009.02.010
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine, Gut, vol.54, issue.8, pp.1121-1126, 2005. ,
DOI : 10.1136/gut.2004.049460
Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease, Gastroenterology, vol.141, issue.5, pp.1621-1628, 2011. ,
DOI : 10.1053/j.gastro.2011.06.050
URL : https://hal.archives-ouvertes.fr/hal-00631539
Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trial, Gastroenterology, vol.110, issue.5, pp.1416-1437, 1996. ,
DOI : 10.1053/gast.1996.v110.pm8613046
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative??Colitis, Gastroenterology, vol.150, issue.2, pp.380-388, 2016. ,
DOI : 10.1053/j.gastro.2015.10.050
URL : https://hal.archives-ouvertes.fr/hal-01303796
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy, New England Journal of Medicine, vol.330, issue.26, pp.1841-1846, 1994. ,
DOI : 10.1056/NEJM199406303302601
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis, Gastroenterology, vol.120, issue.6, pp.1323-1329, 2001. ,
DOI : 10.1053/gast.2001.23983
Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.4, issue.6, pp.760-765, 2006. ,
DOI : 10.1016/j.cgh.2006.04.001
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.369, issue.8, pp.699-710, 2013. ,
DOI : 10.1056/NEJMoa1215734
On behalf of the European Crohn's and Colitis Organisation (ECCO) European, Evidence based consensus on surgery for ulcerative colitis, Journal of Crohn's and Colitis, pp.4-25, 2015. ,
A Laparoscopic Approach Does Reduce Short-Term Complications in Patients Undergoing Ileal Pouch-Anal Anastomosis, Diseases of the Colon & Rectum, vol.54, issue.2, pp.176-182, 2011. ,
DOI : 10.1007/DCR.0b013e3181fb4232
Significantly Increased Pregnancy Rates After Laparoscopic Restorative Proctocolectomy, Annals of Surgery, vol.256, issue.6, pp.1045-1048, 2012. ,
DOI : 10.1097/SLA.0b013e318250caa9
Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications, British Journal of Surgery, vol.44, issue.3, pp.404-409, 2010. ,
DOI : 10.1002/bjs.6874
Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry, Annals of the Rheumatic Diseases, vol.70, issue.4, pp.616-639, 2011. ,
DOI : 10.1136/ard.2010.137422
URL : https://hal.archives-ouvertes.fr/hal-00875446
O07 LONG-TERM SAFETY OF INFLIXIMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER COHORT STUDY, Journal of Crohn's and Colitis Supplements, vol.1, issue.1, pp.501-509, 2009. ,
DOI : 10.1016/S1873-9954(07)70009-5
Reversible bilateral optic neuritis after Infliximab discontinuation in a patient with Crohn's disease, Journal of Crohn's and Colitis, vol.3, issue.3, pp.212-216, 2009. ,
DOI : 10.1016/j.crohns.2009.04.001
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT??? Registry, The American Journal of Gastroenterology, vol.31, issue.9, pp.1409-1431, 2012. ,
DOI : 10.3899/jrheum.100347
Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease, Gastroenterology, vol.143, issue.2, pp.390-399, 2012. ,
DOI : 10.1053/j.gastro.2012.05.004
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays, Alimentary Pharmacology & Therapeutics, vol.35, issue.8, pp.765-71, 2012. ,
DOI : 10.1111/apt.12030
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease, The American Journal of Gastroenterology, vol.26, issue.5, pp.1133-1142, 2010. ,
DOI : 10.1053/j.gastro.2006.11.041
Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.19, issue.12, pp.2568-76, 2013. ,
DOI : 10.1097/MIB.0b013e3182a77b41
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab, Gut, vol.18, issue.(Suppl 1), pp.1258-64, 2014. ,
DOI : 10.1136/gutjnl-2013-305259
Individualised infliximab regimen using therapeutic drug monitoring: a prospective controlled trough level adapted infliximab treatment trial (TAXIT), UEGW 2013. J. of Crohn's and Colitis ,
Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis, Alimentary Pharmacology & Therapeutics, vol.11, issue.12, pp.1293-1299, 2016. ,
DOI : 10.1111/apt.13631
The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study, Gut, vol.46, issue.(Suppl 6), pp.249-255, 2016. ,
DOI : 10.1136/gutjnl-2014-308099